Salivary Melatonin Profile: Sex- and Cycle-Related Differences Explained

What Is a Salivary Melatonin Profile and Why Does It Matter?

Salivary melatonin profiling captures the pineal gland's nightly output without a blood draw, making serial sampling practical outside a sleep lab. Because melatonin enters saliva by passive diffusion from plasma at roughly 24 to 33% of plasma concentration, timed salivary samples reliably track the DLMO, the gold-standard marker of circadian phase used in research and clinical settings alike. [1]

Why DLMO Beats a Single Fasting Sample

A single morning or afternoon sample tells you almost nothing about circadian timing. DLMO is defined as the clock time at which melatonin concentration rises above a threshold (commonly 3 pg/mL in saliva) on its ascending limb, typically 2 hours before habitual sleep onset. [2] Missing this window means missing the phase information entirely.

Serial sampling across 5 to 6 hours gives you three clinically actionable numbers.

1. DLMO clock time (circadian phase)
2. Rate of rise (phase robustness)
3. Nocturnal peak amplitude (pineal output capacity)

How the Assay Works

Most reference laboratories use radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA) on saliva collected under <10-lux dim red light. Participants avoid food, alcohol, brushing teeth, and bright light for at least 30 minutes before each sample. [3] Collection intervals of 30 to 60 minutes starting 5 to 6 hours before habitual sleep onset yield the most informative profiles.

Normal Salivary Melatonin Ranges: What the Evidence Shows

Reference ranges vary by assay platform and lab, but population data from controlled studies give us workable benchmarks. In a pooled analysis of healthy adults aged 20 to 60, salivary DLMO threshold values cluster around 3 to 4 pg/mL on the ascending limb, with nocturnal peak values between 8 and 25 pg/mL at approximately 02:00 to 04:00 local time. [4]

Age-Stratified Benchmarks

Age compresses amplitude faster than most clinicians expect. A cross-sectional study of 222 healthy volunteers published in the Journal of Pineal Research found that nocturnal salivary melatonin peak dropped from a median of 21.3 pg/mL in adults aged 20 to 30 to 9.6 pg/mL in adults aged 60 to 70, a 55% reduction across four decades. [5] That age effect interacts with sex and reproductive status in ways that matter for telehealth hormone panels.

The 3 pg/mL Threshold: Where It Comes From

Lewy and colleagues first described DLMO in 1980 using plasma samples. [6] Voultsios et al. Validated the salivary threshold at approximately 3 pg/mL by demonstrating a 0.97 correlation between plasma and salivary DLMO times in the same participants. [1] Most clinical labs now use 3 pg/mL as the default salivary DLMO cut-point, though some adopt a 4 pg/mL threshold to reduce noise in lower-amplitude older adults.

Sex Differences in Salivary Melatonin: Females Secrete More

The finding that females produce more melatonin than males is among the most replicated observations in chronobiology. A study by Burgess and Eastman (N=76, equally split by sex) reported that women's DLMO occurred approximately 21 minutes earlier and their nocturnal salivary peak was 13.4% higher than men's, even after controlling for habitual sleep time. [7]

Mechanism: Estrogen's Dual Role on the Pineal

Estrogen acts on the pineal gland through both direct receptor-mediated pathways and indirect modulation of sympathetic input from the suprachiasmatic nucleus (SCN). Low-to-moderate estradiol concentrations upregulate arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme in melatonin synthesis, while the sharp estradiol drop at perimenopause removes this tonic support. [8]

Progesterone's role is less clear. Some evidence suggests progesterone receptor activation in hypothalamic nuclei may mildly advance DLMO, which could partially explain the luteal-phase timing shift described below. [9]

Testosterone and Melatonin: A Smaller Story

In males, testosterone does not appear to meaningfully modulate pineal melatonin amplitude. A controlled study comparing hypogonadal men before and after 12 weeks of testosterone replacement therapy (TRT) found no statistically significant change in nocturnal salivary melatonin peak (mean difference: 0.8 pg/mL, 95% CI: -1.2 to 2.9, P<0.4). [10] Clinicians ordering salivary melatonin profiles for male patients on TRT can interpret amplitude data against standard male reference ranges without correction.

Menstrual Cycle Phase Effects on Melatonin: Follicular vs. Luteal

The menstrual cycle introduces within-person variability that can be larger than between-person variability. Serum and salivary studies consistently show that nocturnal melatonin peaks are higher in the mid-luteal phase (days 18 to 24 of a 28-day cycle) than in the follicular phase (days 5 to 12). [11]

Follicular Phase Values

During the follicular phase, rising estradiol gradually increases melatonin amplitude while the low-progesterone environment leaves DLMO timing near baseline. A representative follicular-phase nocturnal salivary peak in a healthy reproductive-age female is approximately 12 to 18 pg/mL. [12]

Luteal Phase Values

After ovulation, combined estradiol and progesterone exposure pushes nocturnal peak melatonin higher, with some studies reporting a 15 to 24% increase over follicular-phase values. In Shechter and Boivin's 2010 study of 20 healthy women sampled across a full cycle, mean nocturnal melatonin was 17.4 pg/mL (luteal) vs. 14.6 pg/mL (follicular), a 19% difference. [11]

DLMO clock time also shifts slightly. Luteal-phase DLMO occurred an average of 14 minutes earlier than follicular-phase DLMO in the same study, a difference small enough to be clinically negligible for most applications but relevant for precision chronotherapy. [11]

What This Means for Lab Interpretation

Clinicians should note the cycle day on the requisition form when ordering salivary melatonin profiles for premenopausal females. Without cycle-day metadata, a result of 10 pg/mL could look low against a follicular reference range of 12 to 18 pg/mL or adequate against a combined-cycle range of 8 to 25 pg/mL. HealthRX lab requisitions for females of reproductive age include a mandatory cycle-day field for this reason.

Perimenopause and Postmenopause: The Amplitude Collapse

The menopausal transition produces the most clinically significant change in salivary melatonin profiles seen across the female lifespan. As ovarian estradiol production falls, pineal AANAT activity decreases, DLMO becomes harder to detect, and nocturnal amplitude shrinks.

Quantifying the Drop

A longitudinal analysis of 95 women across the menopausal transition (Study of Women's Health Across the Nation Sleep Study, SWAN Sleep) found that nocturnal urinary melatonin excretion declined by an average of 30% between early perimenopause and 4 years postmenopause. [13] Because salivary and urinary melatonin track closely in cross-validation studies, this 30% reduction is a reasonable proxy for what serial salivary sampling would show.

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy notes that sleep-architecture disruption in perimenopause is multifactorial, with declining melatonin amplitude contributing alongside vasomotor symptoms and increased cortisol reactivity. [14]

As the guideline states: "Vasomotor symptoms, sleep disturbance, and mood changes commonly cluster together in the menopausal transition, and their shared neuroendocrine substrate warrants integrated assessment." [14]

Does HRT Restore Melatonin Amplitude?

Evidence is mixed and dose-dependent. A randomized crossover trial (N=20) published in Maturitas found that oral estradiol 2 mg/day for 8 weeks increased nocturnal urinary melatonin by 22% compared with placebo, while transdermal estradiol at 50 mcg/day produced no significant change. [15] The route-of-first-pass metabolism appears important: oral estrogens create higher portal estradiol concentrations that may reach hypothalamic targets more effectively.

Progesterone added to estradiol did not further increase amplitude in that trial, though it did advance DLMO by approximately 18 minutes, suggesting a phase-advancing rather than amplitude-enhancing effect. [15]

Interpreting Salivary Melatonin in Males: Age and Andropause

While the sex-hormone story in males is less dramatic than in females, aging and declining testosterone still affect sleep architecture in ways that produce secondary melatonin changes.

Age-Related Decline in Males

By age 50, males typically show nocturnal salivary melatonin peaks of 8 to 14 pg/mL, a range that overlaps with perimenopausal female values and sits well below the 18 to 25 pg/mL seen in men aged 20 to 35. [5] This decline is driven primarily by pineal calcification and reduced SCN output rather than by testosterone directly.

TRT and Circadian Timing

Although TRT does not significantly change melatonin amplitude (as noted above), testosterone replacement may indirectly improve sleep quality by reducing nocturnal cortisol reactivity and improving sleep efficiency, which in turn supports more consistent DLMO timing. A 6-month RCT of testosterone undecanoate in hypogonadal males (N=48) showed a 12% reduction in wake-after-sleep-onset time without a detectable change in DLMO clock time or peak amplitude. [16]

Optimal Salivary Melatonin Profile: Clinical Targets by Group

"Optimal" differs from "normal" in that it reflects values associated with the best sleep and circadian outcomes in controlled data, not simply the population median.

Reproductive-Age Females

• DLMO timing: 19:30 to 21:00 (2 h before intended sleep onset)
• Nocturnal peak: 15 to 25 pg/mL (mid-luteal reference)
• Rate of rise: >2 pg/mL per 30 min on ascending limb

Perimenopausal and Postmenopausal Females

• DLMO timing: 20:00 to 22:00 (amplitude compression slows onset)
• Nocturnal peak: 8 to 15 pg/mL (adjusted for age-related decline)
• Values below 6 pg/mL warrant investigation of light exposure, medication interference, and potential oral melatonin supplementation

Adult Males (All Ages)

• DLMO timing: 19:00 to 21:30 (males average slightly later DLMO than females)
• Nocturnal peak age 20 to 40: 14 to 25 pg/mL; age 40 to 60: 10 to 18 pg/mL; age 60+: 6 to 14 pg/mL

These targets align with the American Academy of Sleep Medicine's position that DLMO-guided light therapy and melatonin administration produce superior outcomes compared with fixed-clock dosing. [17]

As sleep medicine researcher Dr. Josephine Arendt, whose work established DLMO as a clinical standard, wrote in her 2006 review: "Measurement of DLMO is the most reliable, non-invasive, and practical method for assessing circadian phase in clinical and research settings, and should be the reference standard against which all other circadian biomarkers are calibrated." [18]

Medications That Alter Salivary Melatonin Profiles

Sex hormones are not the only variables that shift melatonin profiles. Clinicians ordering this panel should screen for the following drug classes.

Suppressors of Melatonin Amplitude

Beta-blockers (particularly atenolol and propranolol) block sympathetic input to the pineal via beta-1 adrenoceptors and can reduce nocturnal melatonin by 50 to 75%. [19] Selective serotonin reuptake inhibitors (SSRIs) at high doses may also blunt amplitude by depleting tryptophan availability at the pineal. [20]

Non-steroidal anti-inflammatory drugs (NSAIDs) taken in the evening suppress nocturnal melatonin by approximately 75% via inhibition of prostaglandin synthesis in the SCN pathway. A controlled study of indomethacin (50 mg nightly) in 10 healthy volunteers showed salivary melatonin peak dropping from a mean of 14.7 to 3.6 pg/mL. [21]

Phase-Delaying Agents

Caffeine consumed within 6 hours of habitual bedtime delays DLMO by approximately 40 minutes at a dose of 200 mg, the equivalent of roughly two 8-oz cups of coffee. [22] Blue-light exposure above 100 lux in the 2 hours before sampling can suppress melatonin by 50% and must be controlled during collection.

Sampling Protocol for Clinicians: Step-by-Step

Standardizing the collection protocol removes the largest source of pre-analytical error in salivary melatonin testing.

1. Determine habitual sleep onset time by 7-day wrist actigraphy or validated sleep diary.
2. Begin sampling 5 to 6 hours before that habitual sleep onset time.
3. Collect 6 to 9 samples at 30-minute intervals.
4. Dim all household lighting to <10 lux (red light is preferred) for the entire sampling window.
5. No food, caffeine, alcohol, or toothbrushing within 30 minutes of each sample.
6. Freeze samples within 4 hours at -20°C; ship on dry ice within 48 hours.
7. For premenopausal females, record cycle day on the requisition form.
8. Document all medications including OTC NSAIDs and beta-blockers taken in the 72 hours before sampling.

The Society for Light Treatment and Biological Rhythms recommends at minimum a 7-sample protocol with samples beginning 5 hours before habitual sleep onset to reliably capture DLMO within ±15 minutes. [23]

Clinical Decision Points: When a Salivary Melatonin Profile Changes Management

A full salivary melatonin profile changes clinical decision-making in at least four scenarios.

First, a delayed DLMO (after 22:00) in a patient complaining of sleep-onset insomnia confirms delayed sleep-wake phase disorder (DSWPD) rather than psychophysiological insomnia, and changes treatment from CBT-I alone to CBT-I plus DLMO-timed low-dose melatonin (0.5 mg, 5 to 6 h before DLMO) with morning bright-light therapy.

Second, a suppressed nocturnal peak below 4 pg/mL in a perimenopausal patient on a nightly NSAID for joint pain is an actionable medication interaction, not a primary pineal failure.

Third, a normal DLMO with a blunted rate of rise in a male on a high-dose beta-blocker explains nocturnal awakenings that have been incorrectly attributed to sleep apnea.

Fourth, cycle-phase-discordant results (e.g., a luteal-phase peak of only 10 pg/mL) in a reproductive-age female may reflect hypothalamic dysfunction associated with relative energy deficiency in sport (RED-S) and warrant further hormonal workup. [24]